Loading
DUSP2 (Dual specificity protein phosphatase 2) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
Dephosphorylates both phosphorylated Thr and Tyr residues in MAPK1, and dephosphorylation of phosphotyrosine is slightly faster than that of phosphothreonine. Can dephosphorylate MAPK1.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
In plain words · DUSP2 (Dual specificity protein phosphatase 2) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
DUSP2 (Dual specificity protein phosphatase 2) is an enzyme. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
Dephosphorylates both phosphorylated Thr and Tyr residues in MAPK1, and dephosphorylation of phosphotyrosine is slightly faster than that of phosphothreonine. Can dephosphorylate MAPK1.
No product in this corpus aims at DUSP2 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA DUSP2: RNA tissue enhanced (bone marrow 122 nTPM); blood lineage group enriched (NK-cells 148 nTPM, T-cells 200 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas DUSP2 tissue; Open Targets ENSG00000158050 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Rohan et al, Science, 1993, "PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase". Source.
Sources: HGNC HGNC:3068 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q05923 (protein name, function text, keywords and locations (REST API)); CIViC gene DUSP2 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0))
Dephosphorylates both phosphorylated Thr and Tyr residues in MAPK1, and dephosphorylation of phosphotyrosine is slightly faster than that of phosphothreonine. Can dephosphorylate MAPK1. Location: Nucleus (UniProt). Locus 2q11.2 (HGNC).
RNA: tissue enhanced (bone marrow 122 nTPM), detected in many normal tissues. Blood: group enriched (NK-cells 148 nTPM, T-cells 200 nTPM).
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"DUSP2" OR ABSTRACT:"DUSP2" OR TITLE:"dual specificity phosphatase 2" OR ABSTRACT:"dual specificity phosphatase 2" OR TITLE:"Dual specificity protein phosphatase 2" OR ABSTRACT:"Dual specificity protein phosphatase 2" OR TITLE:"PAC-1" OR ABSTRACT:"PAC-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DUSP2, not a curated reading list.